
(in thousands)	June 30, 2026		December 31, 2025
Current assets
Work-in-process	$	58	$	—
Finished goods	1,620		1,852
Total inventory, current	$	1,678	$	1,852
Non-Current assets
Raw materials	$	934	$	934
Work-in-process	5,587		5,996
Finished goods	1,935		2,238
Total inventory, non-current	8,456		9,168
Total inventory	$	10,134	$	11,020

Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company evaluates the risk of excess inventory and product expiry by evaluating current and future product demand relative to product shelf life, taking into account all possible alternative uses for the inventory available in the ordinary course of business. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, patient usage and generic competition. The Company’s inventory balance consisted of $7.1 million of HETLIOZ® product and $3.1 million of other products as of June 30, 2026. The Company’s inventory balance consisted of $7.8 million of HETLIOZ® product and $3.2 million of other products as of December 31, 2025.